The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. Lilly said Thursday that its top-selling drugs,

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a significantly accelerated approval review.

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication more accessible nationwide.

Eli Lilly will cut the price of its most commonly prescribed insulin products by 70% and expand a program that caps patient costs at $35 per month, the company said on Wednesday. "While the current healthcare system provides access to insulin for most ...

Eli Lilly CEO David Ricks told CNBC June 29 that the drugmaker will look for new ways to cut insulin prices in the face of competition from Walmart, which launched its own private label insulin at nearly half the price of Eli Lilly’s. The analog insulin ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica medications for diabetes and weight loss.

The list price is $137.35 per vial. This story is from Kaiser Health News When Erin Gilmer filled her insulin prescription at a Denver-area Walgreens in January, she paid $8.50. U.S. taxpayers paid another $280.51. “It eats at me to know that taxpayer ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and revenue.